In May 2020, a group of researchers published an article 'Design and synthesis of styrenylcyclopropylamine LSD1 inhibitors' (, describing the investigation of mechanism-based inhibitors of lysine-specific demethylase LSD1. LSD1 has a FAD co-factor which is covalently modified by the cyclopropylamine in compound 34 likely through an electron-transfer mechanism.

Compound 34 shows anti-tumor activity and oral efficiency in xenograft model and contains 2-azaspiro[3.3]heptane moiety which provided an improvement to in vitro microsomal stability over the corresponding piperidine analogs.

We have made a set of Building Blocks, which contain such moiety – the perfect start for your research!